AOTMiT: Big changes in the chemotherapy catalog?

The agenda includes:

1 Prepare a position paper on reimbursement of Kinpeygo (budesonide) technology under the drug program "Treatment of patients with primary IgA nephropathy (ICD-10: N02.8)";

2 Prepare an opinion on the draft health policy program of the local government unit "Regional Health Program - Cardiac Rehabilitation module";

3 Prepare an opinion on the transfer of cetuximab from the drug program B.52. "Treatment of squamous cell carcinoma of the organs of the head and neck" to the catalog of reimbursed drugs in chemotherapy;

4 Prepare an opinion on the transfer of cetuximab from drug program B.4. "Treatment of patients with colorectal cancer (ICD-10: C18-20)" to the catalog of reimbursed drugs in chemotherapy;

5 Prepare an opinion on the transfer of panitumumab from drug program B.4. "Treatment of patients with colorectal cancer (ICD-10: C18-20)" to the catalog of reimbursed drugs in chemotherapy;

6 Prepare an opinion on the transfer of temsyrolimus from drug program B.10. "Treatment of patients with renal cell carcinoma (ICD-10: C64)" to the catalog of reimbursable drugs in chemotherapy to the catalog of reimbursable drugs in chemotherapy;

7 Prepare an opinion on the transfer of axitinib from drug program B.10. "Treatment of patients with renal cell carcinoma (ICD-10: C64)" to the catalog of drugs reimbursed in chemotherapy to the catalog of drugs reimbursed in chemotherapy;

8 Prepare an opinion on the transfer of trabectedin from drug program B.8. "Treatment of patients with soft tissue sarcomas (ICD-10: C48, C49)" to the catalog of reimbursed drugs in chemotherapy;

9 Prepare an opinion on the expansion of the chemotherapy catalog to include ICD- 10 codes: - C48 Malignant neoplasm of the retroperitoneal space and peritoneum, - C57 Malignant neoplasm of other and unspecified female genital organs; in Appendix C.22;

10. Prepare an opinion on the continuation of reimbursement in off-label indications for the active substances: enoxaparinum natricum, nadroparinum calcicum in indications:

- Antiphospholipid syndrome or its complications - prophylaxis and anticoagulant treatment;

- Antiphospholipid syndrome - diagnosis;

- Protein C deficiency or protein S deficiency - diagnosis;

- Thrombophilic lesions other than those specified in the SmPC in children under 18 years of age - prophylaxis and treatment; - malignant diseases in cases other than those specified in the SmPC - prophylaxis and anticoagulant treatment;

- bridging therapy instead of vitamin K antagonist (VKA) or other anticoagulants in pregnant women after valve implantation and with a valvular defect;

- Acute coronary syndromes in cases other than those listed in the SmPC;

- Conditions requiring chronic use of vitamin K antagonists (VKAs) (with periodic evaluation of the possibility of returning to VKA use) in patients for whom VKA treatment is not satisfactory due to: a. complications (or anticipated high risk of complications, including hemorrhagic complications) during VKA use, b. frequent non-therapeutic or excessively elevated INR values, c. objective difficulties with sufficiently frequent INR control, d. recurrence of venous thromboembolism during VKA use.

Source: AOTMiT